LUNG CANCER

Is the initial feasibility of lobectomy for stage I non-small cell lung cancer in severe heterogeneous emphysema justified by long-term survival?

Antonio E Martin-Ucar, Khaleel R Fareed, Apostolos Nakas, Paul Vaughan, John G Edwards, David A Waller

Background: The feasibility of anatomical lobectomy in patients with bronchial carcinoma in an area of severe heterogeneous emphysema whose respiratory reserve is outside operability guidelines has previously been confirmed. A review was undertaken to determine whether this approach is justified by long-term survival.

Methods: A single surgeon’s 8 year experience of 118 consecutive patients (74 men) of median age 70 years (range 45–84) who underwent upper lobectomy for pathological stage I non-small cell lung cancer (NSCLC) was reviewed. The preoperative characteristics, perioperative course and survival of the 27 cases with severe heterogeneous emphysema of apical distribution and a predicted postoperative forced expiratory volume in 1 s (ppoFEV1) of <40% (lobarLVRS group) were compared with the remaining 91 cases with a ppoFEV1 of >40% (control group).

Results: Postoperative mortality was 1 of 27 in the lobarLVRS group and 2 of 91 in the control group (p = NS). Five-year survival in the lobarLVRS group was 35% compared with 65% in the control group without concomitant severe emphysema (p = 0.001), although rates of tumour recurrence were similar.

Conclusions: Long-term survival after lobarLVRS for stage I lung cancer is limited by physiological rather than oncological factors. However, outcomes are still better than those reported for any other modality of treatment in this group of high-risk patients. This finding justifies the decision to offer lobectomy in these selected cases.

METHODS

Over an 8 year period (April 1997 to March 2005), 118 patients (74 men) underwent upper lobectomy with systematic lymph node dissection for stage I NSCLC under a single surgeon’s care. Twenty-seven (23%) had severe heterogeneous emphysema of apical distribution with a predicted ppoFEV1 of <40% (lobarLVRS group). Their perioperative course, tumour recurrence and survival were compared with the remaining 91 (77%) patients (control group).

Preoperative characteristics

The median age of the patients was 69 years (range 45–84). Twenty-eight patients (24%) were aged >75 years. The median FEV1 was 70% predicted (range 17–118) with a median ppoFEV1 of 54% (range 14–99). The median preoperative carbon monoxide transfer factor (TLCO) in the lobarLVRS group was 47% predicted (range 32–97). The preoperative characteristics and operative details of the two groups are shown in table 1.

Selection criteria

Resectability was defined by a staging CT scan with a negative cervical mediastinoscopy if lymph nodes were >1 cm in their short axis on the CT scan. We now perform an integrated PET/CT scan but it was not available during the period of the study. The ppoFEV1 was calculated according to a segment counting equation system that we have used since our original report.11 Fitness for surgery for lobectomy was defined by ppoFEV1 >40%. In cases where ppoFEV1 was <40%, a lung perfusion scan with regional distribution was performed to confirm that the cancer was located within an area of emphysema (fig 1).15 Based on the results of the perfusion scan, we defined a Q score as the fraction of perfusion of the affected lung region.

Abbreviations: LVRS, lung volume reduction surgery; NSCLC, non-small cell lung cancer; ppoFEV1, predicted postoperative forced expiratory volume in 1 s; TLCO, carbon monoxide transfer factor.
Q score of <10 (<10% of total) would define a lung region hypoperfused due to emphysema. However, we do not use the Q score to calculate ppOFEV₁ as it is a non-anatomical method and the three zones do not correspond with the anatomical lobes. The selection criteria for these patients followed our standard selection for LVRS.¹⁴ Thus, patients with a ppOFEV₁ <40% and homogeneous emphysema on perfusion scintigraphy were excluded and received non-surgical treatment because of their high risk of perioperative death.¹⁵

All patients were followed up in the surgical outpatient clinic and survival was confirmed via a national registry.

Statistical analysis

The data are presented as median (range) and number (%) unless stated otherwise. Univariate analysis was performed using the χ² test for qualitative data and the Wilcoxon rank test for quantitative data. Postoperative survival was plotted according to the Kaplan-Meier method and any difference in survival between the groups was evaluated with the log-rank test. Statistical significance was defined by p values <0.05 throughout the study.

RESULTS

There were 65 right upper lobectomies and 53 left upper lobectomies with no differences in distribution between the two groups (table 1). In the lobarLVRS and control groups, histological examination revealed adenocarcinoma in 6 (22%) and 36 cases (40%), squamous cell carcinoma in 17 (63%) and 42 cases (46%), and large cell carcinoma/undifferentiated in 4 (15%) and 13 cases (14%), respectively. Four patients (15%) in the lobarLVRS group and 21 (23%) in the control group had pathological stage Ia disease while 23 and 70 had stage Ib disease in the two groups.

Postoperative course

There were three postoperative deaths (2.5%). In the lobarLVRS group a 76-year-old man (ppOFEV₁ 20%) died of MRSA pneumonia 26 days after a right upper lobectomy. In the control group two patients (ppOFEV₁ 52% and 41%) died of myocardial infarction within 48 h of surgery. The median duration of chest drainage was 5 days (range 1–36) and median hospital stay was 7.5 days (range 3–63). There were no differences between the two groups (table 2).
Survival
At the end of the study 26 patients (76.5%) were alive. With a median follow-up of 57 months (range 1–95), the mean (SE) overall 5 year survival was 58.3 (5)%.

DISCUSSION
In recent years we have achieved a better understanding of the consequences of surgery for end-stage emphysema and the management of its complications. This has led doctors to aim to extend the indications for surgery for NSCLC to patients previously deemed unfit for surgery due to concomitant severe emphysema.

To date, the limited data available include mostly patients undergoing sublobar resections in areas of emphysema and feasibility studies of lobectomy for NSCLC on an emphysematous lung. The rationale for performing sublobar resections for early stage NSCLC is based on the principle that surgery only achieves control of local disease that can be achieved with limited removal of lung parenchyma, therefore minimising morbidity/mortality. We have previously reported a case-match comparative study between anatomical segmentectomy and lobectomy for early NSCLC in compromised patients and obtained similarly good outcomes in both groups.

The difference from the current report is that most of the patients in that study suffered from cancer located in the lower lobes. However, reasonable doubts still remain about the oncological value of sublobar or non-anatomical resections for NSCLC.

Our report of “lobarLVRS” did concur with other authors in that lobectomy for carcinoma in patients with heterogeneous emphysema with severely impaired respiratory reserve is feasible with acceptable mortality and with preservation/improvement of the respiratory function after surgery.

However, there are very few data on the long-term outcomes of these patients to determine whether this aggressive approach is justified by survival. Cerfolio et al. reported a 5 year survival in patients with stage I disease of 54% which compares favourably with our series. In addition, in an extensive series of 106 patients (73 undergoing lobectomy), Magdeleinat et al. reported a hospital mortality rate of 8.5% with a 5 year survival of 33% (44% in stage I compared with 35% in our series). We note with interest that, in their report, spirometric values were better and the patients were younger than in our series. Birim et al. reported a 5 year survival of 36% after surgery for early carcinoma in a high-risk group (according to the Charlson comorbidity index).

We did not find significant differences in terms of cancer recurrence between the groups. Our findings concur with those of Sekine and colleagues who reported an increase in non-cancer related death in patients undergoing pulmonary resection for cancer with concomitant chronic obstructive pulmonary disease (COPD).

It is also important to take into consideration the natural history of patients with severe emphysema in the absence of lung cancer. Although the data are limited in terms of follow-up, some of the recent reports of patients undergoing LVRS for heterogeneous emphysema did include long-term survival. The National Emphysema Treatment Trial Research Group (NETT) reported a 5 year survival of 60% in both surgical and medical groups. Other reports are similar with survival rates of 56–71% at 4 or 5 years after LVRS. A recent follow-on report of the NETT trial estimates survival of around 60% 5 years after LVRS. The implication for our series is that the expected survival for the patients in our lobarLVRS group is less than in the control group because of the COPD, so one could not expect similar survival between the groups after surgery.

Another important point to consider when deciding on the therapeutic approach in this group of patients is non-surgical treatment options. There is very little evidence on the use of radical radiotherapy in medically inoperable patients with lung cancer. The subgroup analysis of the CHART trial reported 5 year survival rates of 12–18% depending on the method of delivery of radical radiotherapy. Results of survival of non-randomised studies vary between 0% and 42% at 5 years.

We acknowledge the limitations of our study. It is the result of a retrospective study and is not randomised. Data and follow-up were complete in all cases, but information on patients who did not undergo surgery was not available. Also, the use of other preoperative tests such as measurement of carbon monoxide transfer factor and nuclear perfusion scans were not obtained in all patients in the control group so they are not included in the report. The follow-up protocol does not

<table>
<thead>
<tr>
<th>Event</th>
<th>Median (25–75% interquartile range)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital mortality</td>
<td>1 (3.7%)</td>
<td>2 (2.2%)</td>
</tr>
<tr>
<td>Hospital stay (days)</td>
<td>8 (5.5–13)</td>
<td>7 (6–11)</td>
</tr>
<tr>
<td>Duration of drainage (days)</td>
<td>5 (3.5–10)</td>
<td>5 (4–7)</td>
</tr>
<tr>
<td>Stage Ia/Ib</td>
<td>4.23</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of drainage (days)</td>
<td>21–70</td>
<td>NS</td>
</tr>
</tbody>
</table>

LVRS, lung volume reduction surgery.
include routine CT scans to exclude recurrences unless it is indicated by clinical examination, symptoms or new abnormalities on the chest radiograph.

In summary, we have followed on our feasibility report with a long-term follow-up study of a cohort of patients undergoing upper lobectomy for stage I lung cancer in an emphysematous lobe who would be suitable for LVRS but not for lobectomy according to guidelines. The long-term results are affected by death without evidence of cancer recurrence. However, the survival is better than other reported modalities of treatment. This aggressive approach is therefore justified in this group of high-risk patients. A prospective randomised controlled trial comparing surgery and radical radiotherapy is needed to confirm our conclusions.

ACKNOWLEDGEMENTS

The authors thank Drs K J West, J Entwistle and M Peake for their help in the clinical management of these patients.

Authors’ affiliations

Antonio E Martin-Ucar, Khaled R Fareed, Apostolos Nakas, Paul Vaughan, John G Edwards, David A Waller, Department of Thoracic Surgery, Glenfield Hospital, Leicester, UK

Competing interests: None.

REFERENCES


Table 3 Long-term results expressed as median (25–75% interquartile range) or n (%) 

<table>
<thead>
<tr>
<th>Treatment</th>
<th>LobarLVRS (N = 27)</th>
<th>Lobectomy (N = 91)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up (months)</td>
<td>57 (29–72)</td>
<td>57 (36–75)</td>
<td>NS</td>
</tr>
<tr>
<td>Total recurrence</td>
<td>6 (22%)</td>
<td>16 (18%)</td>
<td>NS</td>
</tr>
<tr>
<td>Locoregional recurrence</td>
<td>3 (11%)</td>
<td>10 (11%)</td>
<td>NS</td>
</tr>
<tr>
<td>Mean (SE) actuarial 3 year survival</td>
<td>48 (11%)</td>
<td>75 (4%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mean (SE) actuarial 5 year survival</td>
<td>35 (11%)</td>
<td>65 (5%)</td>
<td>0.001</td>
</tr>
</tbody>
</table>